Drug Price Transparency Act of 2021
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Apr 29, 2021)
Drug Price Transparency Act of 2021
This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws.
Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.
What just happenedApr 29, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who’s behind it
- Introduced in SenateApr 29, 2021
- Apr 29, 2021IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Apr 29, 2021IntroReferral10000
Introduced in Senate